Phathom Pharmaceuticals demonstrates a solid early-stage commercial execution with VOQUEZNA, evidenced by rapid prescription growth and expanding prescriber adoption, particularly in primary care. The business model is well differentiated through its novel PCAB technology and strategic focus on reg…
Phathom Pharmaceuticals (PHAT) Q4 2024: VOQUEZNA Prescriptions Double to 300,000, Accelerating Market Penetration
Phathom Pharmaceuticals significantly expanded VOQUEZNA's market footprint in 2024, with prescriptions more than doubling and strong prescriber adoption driving momentum. The company is prioritizing primary care penetration and direct-to-consumer campaigns to sustain growth while advancing clinical development for new indications. Upcoming catalysts include a Phase 2 eosinophilic esophagitis trial and a new consumer marketing campaign, positioning PHAT for continued expansion amid typical industry seasonality.
Summary
- Commercial Expansion: Rapid growth in VOQUEZNA prescriptions reflects successful market adoption and broad prescriber engagement.
- Strategic Focus: Emphasis on primary care outreach and enhanced direct-to-consumer marketing to drive volume and brand awareness.
- Pipeline Development: Advancing Phase 2 trial for eosinophilic esophagitis and developing an orally disintegrating tablet to extend product lifecycle.
Business Overview
Phathom Pharmaceuticals is a biopharmaceutical company specializing in novel gastrointestinal treatments. Its core revenue driver is VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB) approved for gastroesophageal reflux disease (GERD) and Helicobacter pylori infection. The company generates revenue primarily through sales of VOQUEZNA tablets and combination therapies such as VOQUEZNA TRIPLE PAK and DUAL PAK.
Performance Analysis
In 2024, Phathom reported net revenues of $55.3 million from VOQUEZNA, marking its first full year of commercial availability. The fourth quarter alone generated $29.7 million, representing an 81% sequential increase driven by the July approval for non-erosive GERD. This growth was supported by expanding prescriber adoption and strong refill rates, with over 300,000 prescriptions filled since launch, more than doubling from the prior quarter.
Gross margin improved to 87% in Q4, reflecting efficient cost management despite significant investment in marketing and commercial infrastructure. Operating expenses increased, particularly in selling, general and administrative (SG&A) costs, which rose due to expanded direct-to-consumer (DTC) advertising and sales force growth. Research and development (R&D) expenses declined as clinical trial activities related to earlier studies wound down.
- Prescription Momentum: Filled prescriptions surged 110% since the last earnings report, with over 118,000 scripts filled in Q4 alone.
- Prescriber Base Growth: The number of healthcare providers writing VOQUEZNA scripts expanded by over 47% to more than 20,000, with primary care physicians surpassing gastroenterologists in cumulative writers.
- Refill and Persistence: Approximately 70% refill rate in Q4 indicates strong patient adherence, comparable to proton pump inhibitor (PPI) therapy patterns.
The financial results reflect a successful launch phase with robust demand, yet the company anticipates typical industry seasonality to temper Q1 2025 revenues. Nevertheless, management remains confident in achieving consensus full-year revenue estimates near $165 million, supported by ongoing commercial investments and pipeline advancement.
Executive Commentary
"Our momentum continues to accelerate, driven by broad, high-quality commercial access, consistent refills, and a growing base of new prescribers across both gastroenterology and primary care. We believe we are on the path to blockbuster success and remain confident that the strong foundation we have built will propel sustained growth."
Terrie Curran, President and CEO
"The combination of new primary care doctors starting to adopt VOQUEZNA, increased physician repeat prescribing, and our direct-to-consumer campaign driving patient requests is fueling new patient starts. We believe focusing on primary care adoption and expanding DTC efforts will be pivotal drivers of growth in 2025."
Martin Gilligan, Chief Commercial Officer
Strategic Positioning
1. Primary Care Penetration
Phathom is strategically prioritizing primary care physicians (PCPs), who represent the largest group treating GERD. With PCP cumulative writers now exceeding gastroenterologists, the company is intensifying sales outreach and education to increase both the number and frequency of PCP prescriptions, aiming to displace traditional PPIs as first-line therapy.
2. Direct-to-Consumer Marketing Expansion
The ongoing "VOQUEZNA Can Kick Some Acid" campaign has significantly increased patient awareness and prescription requests, with a 55% rise in physicians reporting patient-driven VOQUEZNA inquiries. Phathom plans to double its DTC investment in the first half of 2025, launching a new campaign featuring authentic patient testimonials to deepen engagement and accelerate demand.
3. Pipeline Development and Lifecycle Management
Phathom is advancing a Phase 2 clinical trial for eosinophilic esophagitis (EoE), a chronic esophageal inflammatory condition, with top-line data expected in 2027. This represents a potential new indication for VOQUEZNA, positioning it as a first-line pre-biologic treatment. Concurrently, development of an orally disintegrating tablet (ODT) aims to address swallowing difficulties in EoE and pediatric patients, extend intellectual property protection, and enable potential over-the-counter (OTC) opportunities.
4. Intellectual Property and Regulatory Strategy
The company submitted a Citizen Petition (CP) to the FDA requesting a 10-year new chemical entity exclusivity extension through 2032. Management is confident in the petition and patent portfolio, with potential litigation planned if necessary. This exclusivity is critical to protecting VOQUEZNA’s market position against generic competition.
5. Commercial Access and Patient Support
VOQUEZNA has secured coverage for over 120 million U.S. commercial lives, with over 80% accessible after a single prior PPI step. The partnership with BlinkRx pharmacy enhances patient affordability and supports higher refill rates, contributing to sustained therapy adherence.
Key Considerations
Phathom’s 2024 performance highlights the company’s ability to execute a complex launch in a competitive, generic-dominated market. Key considerations for investors include:
- Launch Execution: Strong sequential prescription growth and expanding prescriber base validate market acceptance of VOQUEZNA’s differentiated mechanism.
- Cost Structure Dynamics: Increased SG&A expenses reflect deliberate investment in commercial infrastructure and marketing, balancing near-term profitability with long-term growth potential.
- Pipeline Timing: Phase 2 EoE trial initiation and potential Phase 3 on-demand dosing study decisions by mid-2025 will be key catalysts for future value creation.
- Regulatory Exclusivity: Outcome of the FDA citizen petition and patent term extensions are material to protecting revenue streams beyond mid-2030.
- Seasonality Impact: Anticipated Q1 softness is consistent with industry patterns, underscoring the importance of monitoring post-holiday demand normalization.
Risks
Phathom faces risks including potential delays or unfavorable outcomes in the FDA’s review of the exclusivity petition, competitive pressures from generic PPIs, and the inherent uncertainties of clinical development in EoE. Additionally, the company’s heavy reliance on continued commercial investment to drive adoption may pressure margins if demand growth slows or if payer access deteriorates.
Forward Outlook
For Q1 2025, Phathom anticipates a revenue softening due to typical seasonal effects such as holidays and deductible resets. The company expects to return to growth as these factors normalize. Full-year 2025 revenue guidance aligns with consensus estimates of approximately $165 million.
- Non-GAAP operating expenses are forecasted between $360 million and $390 million, reflecting increased investment in the EoE trial and expanded DTC marketing.
- Management plans to evaluate the return on investment of DTC campaigns mid-year to optimize capital allocation.
Takeaways
Phathom’s Q4 2024 results demonstrate a strong commercial launch underpinned by strategic focus on primary care and patient engagement. The company’s ability to sustain momentum through expanded access and marketing will be critical to achieving blockbuster potential. Pipeline progress and regulatory exclusivity outcomes represent key inflection points for long-term value.
- Robust Launch Traction: VOQUEZNA’s rapid prescription growth and prescriber expansion validate market acceptance and effective commercial execution.
- Growth Levers in Place: Targeted primary care outreach and enhanced DTC efforts are poised to drive incremental adoption and patient demand.
- Pipeline and Exclusivity Catalysts: Upcoming Phase 2 EoE data and FDA exclusivity decision will shape Phathom’s competitive positioning and revenue durability.
Conclusion
Phathom Pharmaceuticals has capitalized on a successful VOQUEZNA launch, establishing a strong commercial foundation and advancing key pipeline initiatives. While near-term seasonality and elevated expenses temper profitability, the company’s strategic investments position it well for sustained growth and long-term market leadership.
Industry Read-Through
Phathom’s experience highlights the challenges and opportunities in launching novel therapies within a generic-dominated gastrointestinal market. The emphasis on primary care engagement and patient-driven demand through DTC marketing may serve as a blueprint for similar specialty pharmaceutical launches. Additionally, the pursuit of extended exclusivity via regulatory petitions underscores the importance of intellectual property strategy in protecting innovation in competitive therapeutic classes.